PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
About PROVECTUS BIOPHARMACEUTICALS, INC.
PROVECTUS BIOPHARMS
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $336.1K
- Net income
- -$5.4M
- Total assets
- $697.5K
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
Provectus Biopharmaceuticals, Inc. (PVCT) Stock Price
- Reported a net loss of $5.4M in FY2025.
- Trading 40% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review PROVECTUS BIOPHARMACEUTICALS, INC..
Write a review
News about PROVECTUS BIOPHARMACEUTICALS, INC.
News & sentiment via Polygon.io
Provectus Biopharmaceuticals, Inc.: frequently asked questions
Is Provectus Biopharmaceuticals, Inc. an American company?
Provectus Biopharmaceuticals, Inc. is a US-based company headquartered in Knoxville, Tennessee, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Provectus Biopharmaceuticals, Inc. headquartered?
Provectus Biopharmaceuticals, Inc. is headquartered in Knoxville, Tennessee, United States.
Is Provectus Biopharmaceuticals, Inc. publicly traded?
Yes — Provectus Biopharmaceuticals, Inc. is a publicly traded company. Its stock trades under the ticker symbol PVCT on the OTC.
What does Provectus Biopharmaceuticals, Inc. do?
Provectus Biopharmaceuticals, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
